Implementation of model-informed precision dosing for tamoxifen therapy in patients with breast cancer: A prospective intervention study

Implementation of model-informed precision dosing for tamoxifen therapy in patients with breast cancer: A prospective intervention study

Tamoxifen is an estrogen-receptor (ER) antagonist, used as adjuvant treatment of ER-positive breast cancer. It is converted by CYP2D6 into endoxifen, its most active metabolite. Patients with endoxifen plasma concentrations <16 nM face a higher risk of recurrence. The use of a priori model-inform...

Full description

Saved in:
Bibliographic Details
Main Authors: Ruben Y.M. van Nijnatten, Sanne M. Buijs, Bram C. Agema, Raphaël M.J. Fischer, Inge Ghobadi Moghaddam-Helmantel, Caroline M.E. Contant, Felix E. de Jongh, Auke M.T. Huijben, Manon Kop, Annemieke van der Padt-Pruijsten, Hanneke J.M. Zuetenhorst, Ron H.N. van Schaik, Birgit C.P. Koch, A. Jager, Stijn L.W. Koolen, Ron H.J. Mathijssen
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:Breast
Subjects:
Breast cancer
Estrogen receptor positive
Hormone therapy
Tamoxifen
Endoxifen
Model informed precision dosing
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977625000098
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S0960977625000098

Similar Items